Advancements in complement inhibition for PNH and primary complement–mediated thrombotic microangiopathy

Blood Advances

DOI: 10.1182/bloodadvances.2024015777 Full text (OA) OpenAlex

Authors 0

Author list not loaded yet.

Cited by 0 stored of 15

References 7

Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
2021 New England Journal of Medicine article Immunology and Microbiology Complement system in diseases Open access cited by 1 patent

407

citations
The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria
2020 Blood article Immunology and Microbiology Complement system in diseases Open access cited by 20 patents

137

citations
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria
2024 American Journal of Hematology article Immunology and Microbiology Complement system in diseases Open access

52

citations
One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab
2020 European Journal Of Haematology article Immunology and Microbiology Complement system in diseases Open access

36

citations
Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNH
2024 Blood Advances article Immunology and Microbiology Complement system in diseases Open access

34

citations
Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long‐term results from the phase I/II COMPOSER trial
2023 European Journal Of Haematology article Immunology and Microbiology Complement system in diseases Open access

20

citations
Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study
2024 Advances in Therapy article Immunology and Microbiology Complement system in diseases Open access

20

citations

7 results